These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
| ☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Delaware
|
77-0390628
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification Number)
|
|
308 Dorla Court, Suite 206 Zephyr Cove, Nevada
|
89448
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Large accelerated filer
☐
|
Accelerated filer
☒
|
||
|
Non-accelerated filer
☐
|
(Do not check if a smaller reporting company)
|
Smaller reporting company
☐
|
|
|
Emerging growth company
☐
|
|||
| · |
WE HAVE BEEN AWARDED DAMAGES IN THE AMOUNT OF $439.7 MILLION IN THE “APPLE I” LITIGATION. WE HAVE ALSO RECEIVED A JURY VERDICT IN THE AMOUNT OF $502.6 MILLION IN DAMAGES IN THE “APPLE II” LITIGATION AND WE HAVE REQUESTED THAT THE DAMAGES IN APPLE II LITIGATION BE ENHANCED DUE TO APPLE’S WILLFUL INFRINGEMENT. TAKEN TOGETHER, THESE STATEMENTS MAY IMPLY THAT WE MAY SOON RECEIVE OVER $900 MILLION IN CASH. HOWEVER, (1) APPLE HAS APPEALED THE AWARDS IN BOTH OF THE APPLE I AND APPLE II LITIGATIONS AND THE COURT’S OR JURY’S DECISIONS MAY BE REVERSED OR AMENDED UPON APPEAL, (2) THE COURT MAY NOT AWARD US ENHANCED DAMAGES IN THE APPLE II LITIGATION, OR (3) WE MAY BE UNSUCCESSFUL IN OUR APPEAL OF CERTAIN ACTIONS BY THE PATENT TRIAL AND APPEALS BOARD THAT HAVE BEEN INITIATED BY APPLE OR OTHER PARTIES -- IF ANY OF THESE OCCUR, THEY MAY HAVE THE AFFECT OF THWARTING ENTIRELY, OR REDUCING AND DELAYING PAYMENTS TO US. THE CONTINUATION OF THESE LITIGATIONS IS DISTRACTING TO OUR MANAGEMENT AND EXPENSIVE, AND THIS DISTRACTION AND EXPENSE MAY CONTINUE.
|
| · |
WE HAVE UNDERTAKEN ACTIVITIES TO COMMERCIALIZE OUR PRODUCTS AND PATENT PORTFOLIO IN AND OUTSIDE THE UNITED STATES. THESE STATEMENTS MAY IMPLY THAT THE WORLDWIDE MARKET FOR OUR COMMERCIALIZED PRODUCTS IS LARGE AND WILL RESULT IN SIGNIFICANT FUTURE REVENUES FOR US. HOWEVER, COMMERCIALIZATION OF PRODUCTS SUCH AS OURS ARE SUBJECT TO SIGNIFICANT OBSTACLES AND RISKS, INCLUDING BUT NOT LIMITED TO A PERCEPTION BY SOME POTENTIAL PARTNERS AND CUSTOMERS THAT THEY SHOULD AWAIT THE OUTCOME OF THE APPLE I AND APPLE II LITIGATIONS BEFORE ENTERING OR CONSIDERING TO ENTER ANY AGREEMENT WITH US, AND THAT OR OTHER FACTORS MAY LEAD US TO BE UNSUCCESSFUL IN OBTAINING FURTHER LICENSING AGREEMENTS OR MAKING ARRANGEMENTS OR ENTERING CONTRACTS WHICH CREATE SIGNIFICANT FUTURE REVENUES FOR US.
|
|
Page
|
||
|
1
|
||
|
1
|
||
|
1
|
||
|
2
|
||
|
2
|
||
|
3
|
||
|
4
|
||
|
14
|
||
|
19
|
||
|
19
|
||
|
20
|
||
|
20
|
||
|
22
|
||
|
32
|
||
|
33
|
||
|
34
|
||
|
As of
June 30, 2018
|
As of
December 31, 2017
|
|||||||
|
(unaudited)
|
||||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
3,968
|
$
|
3,135
|
||||
|
Accounts receivables
|
2
|
—
|
||||||
|
Investments available for sale
|
724
|
1,453
|
||||||
|
Prepaid expenses and other current assets
|
864
|
591
|
||||||
|
Total current assets
|
5,558
|
5,179
|
||||||
|
Prepaid expenses, non-current
|
1,796
|
1,989
|
||||||
|
Property and equipment, net
|
17
|
7
|
||||||
|
Total assets
|
$
|
7,371
|
$
|
7,175
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable and accrued liabilities
|
$
|
2,966
|
$
|
414
|
||||
|
Accrued payroll and related expenses
|
219
|
2,175
|
||||||
|
Income tax liability
|
399
|
393
|
||||||
|
Deferred revenue, current portion
|
—
|
1,500
|
||||||
|
Total current liabilities
|
3,584
|
4,482
|
||||||
|
Deferred revenue, non-current portion
|
—
|
1,000
|
||||||
|
Other liabilities
|
140
|
140
|
||||||
|
Total liabilities
|
3,724
|
5,622
|
||||||
|
Commitments and contingencies (Note 4)
|
—
|
—
|
||||||
|
Stockholders’ equity:
|
||||||||
|
Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at June 30, 2018 and December 31, 2017, Issued and outstanding: 0 shares at June 30, 2018 and December 31, 2017
|
—
|
—
|
||||||
|
Common stock, par value $0.0001 per share: Authorized: 100,000,000 shares at June 30, 2018 and December 31, 2017, Issued and outstanding: 62,292,808 shares and 59,051,978 shares, at June 30, 2018 and December 31, 2017, respectively
|
6
|
6
|
||||||
|
Additional paid-in capital
|
190,724
|
177,076
|
||||||
|
Accumulated deficit
|
(187,070
|
)
|
(175,516
|
)
|
||||
|
Accumulated other comprehensive loss
|
(13
|
)
|
(13
|
)
|
||||
|
Total stockholders’ equity
|
3,647
|
1,553
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
7,371
|
$
|
7,175
|
||||
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
|
June 30,
2018
|
June 30,
2017
|
June 30,
2018
|
June 30,
2017
|
|||||||||||||
|
Revenue
|
$
|
16
|
$
|
396
|
$
|
22
|
$
|
771
|
||||||||
|
Operating expense:
|
||||||||||||||||
|
Research and development
|
1,186
|
957
|
2,191
|
1,873
|
||||||||||||
|
Selling, general and administrative
|
5,292
|
3,250
|
11,901
|
6,615
|
||||||||||||
|
Total operating expense
|
6,478
|
4,207
|
14,092
|
|
8,488
|
|||||||||||
|
Loss from operations
|
(6,462
|
)
|
(3,811
|
)
|
(14,070
|
)
|
(7,717
|
)
|
||||||||
|
Interest income, net
|
12
|
13
|
20
|
31
|
||||||||||||
|
Loss before taxes
|
(6,450
|
)
|
(3,798
|
)
|
(14,050
|
)
|
(7,686
|
)
|
||||||||
|
Provision for income tax
|
—
|
—
|
(5
|
)
|
(5
|
)
|
||||||||||
|
Net loss
|
$
|
(6,450
|
)
|
$
|
(3,798
|
)
|
$
|
(14,055
|
)
|
$
|
(7,691
|
)
|
||||
|
Basic and diluted loss per share
|
$
|
(0.10
|
)
|
$
|
(0.07
|
)
|
$
|
(0.23
|
)
|
$
|
(0.13
|
)
|
||||
|
Weighted average shares outstanding basic and diluted
|
61,532
|
58,195
|
60,835
|
58,170
|
||||||||||||
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
|
June 30,
2018
|
June 30,
2017
|
June 30,
2018
|
June 30,
2017
|
|||||||||||||
|
Net loss
|
$
|
(6,450
|
)
|
$
|
(3,798
|
)
|
$
|
(14,055
|
)
|
$
|
(7,691
|
)
|
||||
|
Other comprehensive income (loss):
|
||||||||||||||||
|
Change in equity adjustment from foreign currency translation, net of tax
|
—
|
—
|
—
|
(1
|
)
|
|||||||||||
|
Change in unrealized gain on investments, net of tax
|
(1
|
)
|
—
|
—
|
(4
|
)
|
||||||||||
|
Total other comprehensive income gain (loss)
|
(1
|
)
|
—
|
—
|
(5
|
)
|
||||||||||
|
Comprehensive loss
|
$
|
(6,451
|
)
|
$
|
(3,798
|
)
|
$
|
(14,055
|
)
|
$
|
(7,696
|
)
|
||||
|
Six Months
Ended
June 30,
2018
|
Six Months
Ended
June 30,
2017
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$
|
(14,055
|
)
|
$
|
(7,691
|
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation
|
10
|
15
|
||||||
|
Stock-based compensation
|
2,008
|
1,715
|
||||||
|
Changes in assets and liabilities:
|
||||||||
|
Prepaid expenses and other assets
|
(80
|
)
|
(13
|
)
|
||||
|
Accounts payable and accrued liabilities
|
2,552
|
(1,362
|
)
|
|||||
|
Accrued payroll and related expenses
|
(1,923
|
)
|
(1,303
|
)
|
||||
|
Accounts receivables
|
(2
|
)
|
—
|
|||||
|
Income tax liability
|
6
|
(1
|
)
|
|||||
|
Deferred revenue
|
—
|
(750
|
)
|
|||||
|
Net cash used in operating activities
|
(11,484
|
)
|
(9,390
|
)
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Purchase of investments
|
(924
|
)
|
(756
|
)
|
||||
|
Proceeds from sale or maturity of investments
|
1,635
|
5,760
|
||||||
|
Net cash provided by investing activities
|
711
|
5,004
|
||||||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from sale of common stock
|
11,639
|
—
|
||||||
|
Payments of taxes on restricted stock units
|
(33
|
)
|
(29
|
)
|
||||
|
Net cash provided by (used in) financing activities
|
11,606
|
(29
|
)
|
|||||
|
Net change in cash and cash equivalents
|
833
|
(4,415
|
)
|
|||||
|
Cash and cash equivalents, beginning of period
|
3,135
|
6,627
|
||||||
|
Cash and cash equivalents, end of period
|
$
|
3,968
|
$
|
2,212
|
||||
|
Non-cash transactions
|
||||||||
|
Deferred revenue reclassified to retained earnings – ASC 606 adoption
|
$
|
2,500 |
$
|
— | ||||
|
June 30, 2018
|
||||||||||||||||||||||||
|
Adjusted
Cost
|
Unrealized
Gains
|
Unrealized
Losses
|
Fair
Value
|
Cash
and Cash
Equivalents
|
Investments
Available
for Sale
|
|||||||||||||||||||
|
Cash
|
$
|
2,056
|
$
|
-
|
$
|
-
|
$
|
2,056
|
$
|
2,056
|
$
|
-
|
||||||||||||
|
Level 1:
|
||||||||||||||||||||||||
|
Mutual funds
|
1,087
|
-
|
-
|
1,087
|
1,087
|
-
|
||||||||||||||||||
|
U.S. government securities
|
80
|
-
|
-
|
80
|
-
|
80
|
||||||||||||||||||
|
U.S. agency securities
|
1,468
|
1
|
-
|
1,469
|
825
|
644
|
||||||||||||||||||
|
2,635
|
1
|
-
|
2,636
|
1,912
|
724
|
|||||||||||||||||||
|
Total
|
$
|
4,691
|
$
|
1
|
$
|
-
|
$
|
4,692
|
$
|
3,968
|
$
|
724
|
||||||||||||
|
December 31, 2017
|
||||||||||||||||||||||||
|
Adjusted
Cost
|
Unrealized
Gains
|
Unrealized
Losses
|
Fair
Value
|
Cash and
Cash
Equivalents
|
Investments
Available
for Sale
|
|||||||||||||||||||
|
Cash
|
$
|
1,972
|
$
|
—
|
$
|
—
|
$
|
1,972
|
$
|
1,972
|
$
|
—
|
||||||||||||
|
Level 1:
|
||||||||||||||||||||||||
|
Mutual funds
|
616
|
—
|
—
|
616
|
616
|
|||||||||||||||||||
|
U.S. agency securities
|
2,001
|
—
|
(1
|
)
|
2,000
|
547
|
1,453
|
|||||||||||||||||
|
2,617
|
—
|
(1
|
)
|
2,616
|
1,163
|
1,453
|
||||||||||||||||||
|
Total
|
$
|
4,589
|
$
|
—
|
$
|
(1
|
)
|
$
|
4,588
|
$
|
3,135
|
$
|
1,453
|
|||||||||||
|
Original
Number
of
Warrants
Issued
|
Exercise
Price per
Common
Share
|
Exercisable at
December 31,
2017
|
Became
Exercisable
|
Exercised
|
Terminated /
Cancelled /
Expired
|
Exercisable
at June 30,
2018
|
Expiration
Date
|
||||||||||||||||||||
|
25,000
|
$
|
7.00
|
25,000
|
—
|
—
|
—
|
25,000
|
April 2020
|
|||||||||||||||||||
|
25,000
|
—
|
—
|
—
|
25,000
|
|||||||||||||||||||||||
|
·
|
VirnetX
Inc. v. The Mangrove Partners (USCAFC Case 17-1368)
|
|
·
|
VirnetX Inc. v. Cisco Systems, Inc. (USCAFC Case 18-1197-CB) (Appeal of Apple I Case)
|
|
·
|
VirnetX Inc. v. Apple Inc., Cisco Systems, Inc. (USCAFC Case 17-1591)
|
|
Balance Sheet Highlights
|
Reported As of
December 31, 2017
|
Effects of Adopting
Topic 606
|
As of
January 1, 2018
|
|||||||||
|
Current liabilities:
|
||||||||||||
|
Deferred revenue, current portion
|
$
|
1,500
|
$
|
(1,500
|
)
|
$
|
—
|
|||||
|
Total current liabilities
|
$
|
4,482
|
$
|
(1,500
|
)
|
$
|
2,982
|
|||||
|
Deferred revenue, non-current portion
|
1,000
|
(1,000
|
)
|
—
|
||||||||
|
Other liabilities
|
140
|
—
|
140
|
|||||||||
|
Total Liabilities
|
$
|
5,622
|
$
|
(2,500
|
)
|
$
|
3,122
|
|||||
|
Accumulated deficit
|
$
|
(175,516
|
)
|
$
|
2,500
|
$
|
(173,016
|
)
|
||||
|
Total Stockholder’s Equity
|
$
|
1,553
|
$
|
2,500
|
$
|
4,053
|
||||||
|
|
As of
June 30,
2018
Pre-Topic 606
|
Effects of Adopting
Topic 606
|
As of
June 30,
2018
(as reported)
|
|||||||||
|
Deferred revenue, current portion
|
$
|
1,500
|
$
|
(1,500
|
)
|
$
|
—
|
|||||
|
Total current liabilities
|
$
|
5,084
|
$
|
(1,500
|
)
|
$
|
3,584
|
|||||
|
Deferred revenue, non-current portion
|
250
|
(250
|
)
|
—
|
||||||||
|
Other liabilities
|
140
|
—
|
140
|
|||||||||
|
Total liabilities
|
$
|
5,474
|
$
|
(1,750
|
)
|
$
|
3,724
|
|||||
|
Accumulated deficit
|
(188,820
|
)
|
1,750
|
(187,070
|
)
|
|||||||
|
Total stockholders’ equity
|
$
|
1,897
|
$
|
1,750
|
$
|
3,647
|
||||||
|
Income Statement Highlights
|
Six Months Ended
June 30, 2018
Pre-Topic 606
|
Six Months Ended
June 30, 2018
Effects of Adopting
Topic 606
|
Six Months Ended
June 30, 2018
(as reported)
|
|||||||||
|
Revenue
|
$
|
772
|
$
|
(750
|
)
|
$
|
22
|
|||||
|
Loss from operations
|
(13,320
|
)
|
(750
|
)
|
(14,070
|
)
|
||||||
|
Interest income, net
|
20
|
—
|
20
|
|||||||||
|
Loss before taxes
|
(13,300
|
)
|
(750
|
)
|
(14,050
|
)
|
||||||
|
Provision for income taxes
|
(5
|
)
|
—
|
(5
|
)
|
|||||||
|
Net loss
|
$
|
(13,305
|
)
|
$
|
(750
|
)
|
$
|
(14,055
|
)
|
|||
|
Three Months Ended
June 30, 2018
Pre-Topic 606
|
Three Months Ended
June 30, 2018
Effects of Adopting
Topic 606
|
Three Months Ended
June 30, 2018
(as reported)
|
||||||||||
|
Revenue
|
$
|
391
|
$
|
(375
|
)
|
$
|
16
|
|||||
|
Loss from operations
|
(6,087
|
)
|
(375
|
)
|
(6,462
|
)
|
||||||
|
Interest income, net
|
12
|
—
|
12
|
|||||||||
|
Loss before taxes
|
(6,075
|
)
|
(375
|
)
|
(6,450
|
)
|
||||||
|
Net loss
|
$
|
(6,075
|
)
|
$
|
(375
|
)
|
$
|
(6,450
|
)
|
|||
|
Cash Flow Statement Highlights
|
Six
Months
Ended
June 30,
2018
Pre- Topic 606
|
Six
Months
Ended
June 30, 2018
Effects of
Adopting Topic
606
|
Six
Months
Ended
June 30,
2018
(as reported)
|
|||||||||
|
Net loss
|
$
|
(13,305
|
)
|
$
|
(750
|
)
|
$
|
(14,055
|
)
|
|||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
|
Deferred revenue
|
(750
|
) |
750
|
—
|
||||||||
|
Net cash used in operating activities
|
(11,484
|
)
|
—
|
(11,484
|
)
|
|||||||
|
·
|
VirnetX Inc. v. The Mangrove Partners (USCAFC Case 17-1368)
|
|
·
|
VirnetX Inc. v. Cisco Systems, Inc. (USCAFC Case 18-1197-CB) (Appeal of Apple I Case)
|
|
·
|
VirnetX Inc. v. Apple Inc., Cisco Systems, Inc. (USCAFC Case 17-1591)
|
| • |
Although to date we have entered into a limited number of settlement and license agreements, we may not be successful in entering into further licensing relationships, or if we are successful in entering into such relationships, the acquisition of them may be expensive, and they, as well as our existing settlement and our existing and pending license agreements may not generate the financial results we expect;
|
|
•
|
Third parties may challenge the validity of our patents;
|
|
•
|
The pendency of our various litigations may cause potential licensees not to do business with us;
|
| • |
We face, and we expect to continue to face, intense competition from new and established competitors who may have superior products and services or better marketing, financial or other capacities than we do; and
|
| • |
It is possible that one or more of our potential customers or licensees develops or otherwise sources products or technologies similar to, competitive with or superior to ours.
|
| • |
New legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs and decrease our revenue. For instance, the United States Supreme Court has recently modified some tests used by the USPTO in granting patents during the past 20 years which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license. In addition, the United States recently enacted sweeping changes to the United States patent system under the Leahy-Smith America Invents Act, including changes that transition the United States from a “first-to-invent” system to a “first to file” system and alter the processes for challenging issued patents;
|
|
•
|
More patent applications are filed each year resulting in longer delays in getting patents issued by the USPTO;
|
|
•
|
Federal courts are becoming more crowded, and as a result, patent enforcement litigation is taking longer; and
|
|
•
|
As patent enforcement becomes more prevalent, it may become more difficult for us to voluntarily license our patents.
|
|
•
|
The need to educate potential customers about our patent rights and our product and service capabilities;
|
| • |
Our customers’ willingness to invest potentially substantial resources and modify their network infrastructures to take advantage of our products;
|
|
•
|
Our customers’ budgetary constraints;
|
|
•
|
The timing of our customers’ budget cycles;
|
|
•
|
Delays caused by customers’ internal review processes; and
|
| • |
Long sales cycles that may increase the risk that our financial resources are exhausted before we are able to generate significant revenue.
|
| • |
Generate revenues or profit from product sales;
|
| • |
Drive adoption of our products;
|
| • |
Attract and retain customers for our products;
|
| • |
Provide appropriate levels of customer training and support for our products;
|
| • |
Implement an effective marketing strategy to promote awareness of our products;
|
| • |
Focus our research and development efforts in areas that generate returns on our efforts;
|
| • |
Anticipate and adapt to changes in our market; or
|
| • |
Protect our products from any system failures or other breaches.
|
| • |
Power loss, transmission cable cuts and other telecommunications failures;
|
| • |
Damage or interruption caused by fire, earthquake, and other natural disasters;
|
| • |
Computer viruses or software defects; and
|
| • |
Physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks and other events beyond our control.
|
| • |
Developments or lack thereof in any then-outstanding litigation;
|
| • |
Quarterly variations in our operating results;
|
| • |
Large purchases or sales of common stock or derivative transactions related to our stock;
|
| • |
Actual or anticipated announcements of new products or services by us or competitors;
|
| • |
General conditions in the markets in which we compete; and
|
| • |
General social, political, economic and financial conditions, including the significant volatility in the global financial markets.
|
|
•
|
Price and volume fluctuations in the overall stock market from time to time;
|
| • |
Volatility in the market prices and trading volumes of companies in our industry or companies that investors consider comparable;
|
|
•
|
Changes in operating performance and stock market valuations of other companies generally, or those in our industry;
|
|
•
|
Sales of shares of our common stock by us or our stockholders;
|
| • |
Failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow us, or our failure to meet these estimates or the expectations of investors;
|
| • |
The financial projections we may provide to the public, any changes in those projections or our failure to meet those projections;
|
|
•
|
Announcements by us or our competitors of new products or services;
|
|
•
|
The public’s reaction to our press releases, other public announcements and filings with the SEC;
|
|
•
|
Rumors and market speculation involving us or other companies in our industry;
|
|
•
|
Actual or anticipated changes in our results of operations;
|
|
•
|
Actual or anticipated developments in our business, our competitors’ businesses or the competitive landscape generally;
|
|
•
|
Litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;
|
|
•
|
Announced or completed acquisitions of businesses or technologies by us or our competitors;
|
|
•
|
New laws or regulations or new interpretations of existing laws or regulations applicable to our business;
|
|
•
|
Changes in accounting standards, policies, guidelines, interpretations or principles;
|
|
•
|
Any significant change in our management; and
|
|
•
|
General economic conditions and slow or negative growth of our markets.
|
| • |
The outcome of actions to enforce our intellectual property rights currently in progress or that we may undertake in the future, and the timing thereof;
|
|
•
|
The amount and timing of receipt of license fees from potential infringers, licensees or customers;
|
|
•
|
The rate of adoption of our patented technologies;
|
| • |
The number of new license arrangements we may execute, or that may expire, within a particular period and the scope of those licenses, including the number of our patents which are licensed, the extent of prior infringement of our patent rights, royalty rates, timing of payment obligations, expiration date etc.;
|
|
•
|
The success of a licensee in selling products that use our patented technologies; and
|
| • |
The amount and timing of expenses related to our patent filings and enforcement proceedings, including litigation, related to our intellectual property rights.
|
| • |
A staggered Board of Directors:
This means that only one or two directors (since we have a five-person Board of Directors) will be up for election at any given annual meeting. This has the effect of delaying the ability of stockholders to affect a change in control of us because it would take two annual meetings to effectively replace a majority of the Board of Directors.
|
| • |
Blank check preferred stock
: Our Board of Directors has the authority to establish the rights, preferences and privileges of our 10,000,000 authorized, but unissued, shares of preferred stock. Therefore, this stock may be issued at the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock can be used to create a “poison pill” which is designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of Directors has the ability to do so in the future, very rapidly and without stockholder approval.
|
| • |
Advance notice requirements for director nominations and for new business to be brought up at stockholder meetings:
Stockholders wishing to submit director nominations or raise matters to a vote of the stockholders must provide notice to us within very specific date windows and in very specific form in order to have the matter voted on at a stockholder meeting. This has the effect of giving our Board of Directors and management more time to react to stockholder proposals generally and could also have the effect of disregarding a stockholder proposal or deferring it to a subsequent meeting to the extent such proposal is not raised properly.
|
| • |
No stockholder actions by written consent:
No stockholder or group of stockholders may take actions rapidly and without prior notice to our Board of Directors and management or to the minority stockholders. Along with the advance notice requirements described above, this provision also gives our Board of Directors and management more time to react to proposed stockholder actions.
|
| • |
Super majority requirement for stockholder amendments to the By-laws:
Stockholder proposals to alter or amend our By-laws or to adopt new By-laws can only be approved by the affirmative vote of at least 66 2/3% of the outstanding shares of our common stock.
|
| • |
No ability of stockholders to call a special meeting of the stockholders:
Only the Board of Directors or management can call special meetings of the stockholders. This could mean that stockholders, even those who represent a significant percentage of our shares of common stock, may need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders.
|
|
VIRNETX HOLDING CORPORATION
|
|||
|
By:
|
/s/ Kendall Larsen
|
||
|
Name
|
Kendall Larsen
|
||
|
Title
|
Chief Executive Officer (Principal Executive Officer)
|
||
|
By:
|
/s/ Richard H. Nance
|
||
|
Name
|
Richard H. Nance
|
||
|
Title
|
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
|
||
|
Date: August 9, 2018
|
|||
|
Exhibit
Number
|
Description
|
|
Certification of the President and Chief Executive Officer pursuant to Exchange Act Rules 13a – 14(a) and 15d – 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
Certification of the Chief Financial Officer pursuant to Exchange Act Rules 13a – 14(a) and 15d – 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
101
|
Interactive Data Files
|
| * |
Portions of this Exhibit have been omitted pursuant to a request for confidential treatment. The omitted portions were filed separately with the Securities and Exchange Commission.
|
| ** |
Filed herewith.
|
| *** |
The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of VirnetX Holding Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|